The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study
Yazar
Bilici, Ahmet
Soran, Atilla
Dogan, Lutfi
Isik, Arda
Ozbas, Serdar
Trabulus, Didem Can
Demirci, Umut
Karanlik, Hasan
SOYDER, AYKUT
DAĞ, AHMET
Dogan, Mutlu
Koksal, Hande
ŞENDUR, MEHMET ALİ NAHİT
Gulcelik, Mehmet Ali
MARALCAN, GÖKTÜRK
Cabioglu, Neslihan
YENİAY, LEVENT
Utkan, Zafer
ŞİMŞEK, TURGAY
Karadurmus, Nuri
Daglar, Gul
Yildiz, Birol
URAS, Cihan
Tukenmez, Mustafa
Yildirim, Ahmet
Kutun, Suat
Ozaslan, Cihangir
Karaman, Niyazi
AKÇAY, Müfide Nuran
Toktaş, Osman
SEZGİN, EFE
Üst veri
Tüm öğe kaydını gösterÖzet
Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM). Methods The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups: those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who received LRT were further divided into two groups: ST after LRT (LRT + ST group) and ST before LRT (ST + LRT group). Results We included 505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group. One hundred and thirteen patients (26.3%) died in the 34-month median follow-up, 85 (35.4%) in the ST group and 28 (10.5%) in LRT group. Local progression was observed in 39 (16.2%) of the patients in the ST group and 18 (6.7%) in the LRT group (p = 0.001). Hazard of death was 60% lower in the LRT group compared with the ST group (HR 0.40, 95% CI 0.30-0.54, p < 0.0001). Conclusion In this prospectively maintained registry study, we found that LRT prolonged survival and decreased locoregional recurrence in the median 3-year follow-up. Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.
Koleksiyonlar
- Makale [92796]